397 related articles for article (PubMed ID: 31955605)
1. Associations Between Obesity and the Effectiveness of Anti-Tumor Necrosis Factor-α Agents in Inflammatory Bowel Disease Patients: A Literature Review and Meta-analysis.
Dai ZH; Xu XT; Ran ZH
Ann Pharmacother; 2020 Aug; 54(8):729-741. PubMed ID: 31955605
[No Abstract] [Full Text] [Related]
2. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis.
Billioud V; Ford AC; Tedesco ED; Colombel JF; Roblin X; Peyrin-Biroulet L
J Crohns Colitis; 2013 Dec; 7(11):853-67. PubMed ID: 23523418
[TBL] [Abstract][Full Text] [Related]
3. Treatment Failure of TNF-α Inhibitors in Obese Patients With Inflammatory Bowel Disease-A Cohort Study.
Madsen KG; Pottegård A; Hallas J; Kjeldsen J
Inflamm Bowel Dis; 2018 Nov; 24(12):2628-2633. PubMed ID: 29788214
[TBL] [Abstract][Full Text] [Related]
4. New strategies in the management of inflammatory bowel disease.
Rutgeerts P; Baert F
Acta Clin Belg; 1999 Oct; 54(5):274-80. PubMed ID: 10555385
[TBL] [Abstract][Full Text] [Related]
5. Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents.
Karmiris K; Bossuyt P; Sorrentino D; Moreels T; Scarcelli A; Legido J; Dotan I; Naismith GD; Jussila A; Preiss JC; Kruis W; Li AC; Bouguen G; Yanai H; Steinwurz F; Katsanos KH; Subramaniam K; Tarabar D; Zaganas IV; Ben-Horin S;
J Crohns Colitis; 2015 May; 9(5):382-9. PubMed ID: 25740813
[TBL] [Abstract][Full Text] [Related]
6. Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases.
Komaki Y; Yamada A; Komaki F; Micic D; Ido A; Sakuraba A
Aliment Pharmacol Ther; 2017 Apr; 45(8):1043-1057. PubMed ID: 28239873
[TBL] [Abstract][Full Text] [Related]
7. Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease.
Harper JW; Sinanan MN; Zisman TL
Inflamm Bowel Dis; 2013 Sep; 19(10):2118-24. PubMed ID: 23863401
[TBL] [Abstract][Full Text] [Related]
8. Analysis of TNF-antagonist switch over time and associated risk factors in the Swiss Inflammatory Bowel Disease Cohort.
Hiroz P; Vavricka SR; Fournier N; Safroneeva E; Pittet V; Rogler G; Schoepfer AM;
Scand J Gastroenterol; 2014 Oct; 49(10):1207-18. PubMed ID: 25120029
[TBL] [Abstract][Full Text] [Related]
9. Effect of Obesity on Risk of Hospitalization, Surgery, and Serious Infection in Biologic-Treated Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study.
Gu P; Luo J; Kim J; Paul P; Limketkai B; Sauk JS; Park S; Parekh N; Zheng K; Rudrapatna V; Syal G; Ha C; McGovern DP; Melmed GY; Fleshner P; Eisenstein S; Ramamoorthy S; Dulai PS; Boland BS; Grunvald E; Mahadevan U; Ohno-Machado L; Sandborn WJ; Singh S
Am J Gastroenterol; 2022 Oct; 117(10):1639-1647. PubMed ID: 35973139
[TBL] [Abstract][Full Text] [Related]
10. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.
Aardoom MA; Veereman G; de Ridder L
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126015
[TBL] [Abstract][Full Text] [Related]
11. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
12. Soluble CD163, a specific macrophage activation marker, is decreased by anti-TNF-α antibody treatment in active inflammatory bowel disease.
Dige A; Støy S; Thomsen KL; Hvas CL; Agnholt J; Dahlerup JF; Møller HJ; Grønbaek H
Scand J Immunol; 2014 Dec; 80(6):417-23. PubMed ID: 25346048
[TBL] [Abstract][Full Text] [Related]
13. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects.
Allez M; Karmiris K; Louis E; Van Assche G; Ben-Horin S; Klein A; Van der Woude J; Baert F; Eliakim R; Katsanos K; Brynskov J; Steinwurz F; Danese S; Vermeire S; Teillaud JL; Lémann M; Chowers Y
J Crohns Colitis; 2010 Oct; 4(4):355-66. PubMed ID: 21122530
[TBL] [Abstract][Full Text] [Related]
14. Suboptimal response to tumor necrosis factor antagonists in inflammatory bowel disease in Latin America: EXPLORE LATAM study.
Balderramo D; Yamamoto-Furusho J; Ponce de León E; de María J; Zubiaurre I; Pedreira S; Lis C; Brion L; de Paula JA
Gastroenterol Hepatol; 2024 Jan; 47(1):51-62. PubMed ID: 37062500
[TBL] [Abstract][Full Text] [Related]
15. Novel agents in the future: Therapy beyond anti-TNF agents in inflammatory bowel disease.
Peng JC; Shen J; Ran ZH
J Dig Dis; 2014 Nov; 15(11):585-90. PubMed ID: 25251263
[TBL] [Abstract][Full Text] [Related]
16. Complications and surgery in the inflammatory bowel diseases biological era.
Sokol H; Seksik P; Cosnes J
Curr Opin Gastroenterol; 2014 Jul; 30(4):378-84. PubMed ID: 24840000
[TBL] [Abstract][Full Text] [Related]
17. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
18. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.
Gisbert JP; Marín AC; McNicholl AG; Chaparro M
Aliment Pharmacol Ther; 2015 Apr; 41(7):613-23. PubMed ID: 25652884
[TBL] [Abstract][Full Text] [Related]
19. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience.
Fréling E; Baumann C; Cuny JF; Bigard MA; Schmutz JL; Barbaud A; Peyrin-Biroulet L
Am J Gastroenterol; 2015 Aug; 110(8):1186-96. PubMed ID: 26195181
[TBL] [Abstract][Full Text] [Related]
20. Cytokine tumor necrosis factor-alpha A promoter gene polymorphism at position -308 G-->A and pediatric inflammatory bowel disease: implications in ulcerative colitis and Crohn's disease.
Sýkora J; Subrt I; Dìdek P; Siala K; Schwarz J; Machalová V; Varvarovská J; Pazdiora P; Pozler O; Stozický F
J Pediatr Gastroenterol Nutr; 2006 May; 42(5):479-87. PubMed ID: 16707968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
